Tech Company Financing Transactions
Epicrispr Biotechnologies Funding Round
California Institute for Regenerative Medicine joined a $8 million funding round for Epicrispr Biotechnologies. The round was recorded on 10/19/2026.
Transaction Overview
Company Name
Announced On
10/19/2026
Transaction Type
Debt
Amount
$8,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to support the ongoing first-in-human clinical development of EPI-321, its lead investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7000 Shoreline Court 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Epicrispr Biotechnologies is building the world's leading therapeutic platform based on the exciting new technology of epigenetic editing. We were founded by genetic medicine pioneer Stanley Qi, Ph.D., whose fundamental work in epigenetic editing includes the invention of CRISPRa (activation) and CRISPRi (interference). We are translating the powerful potential of epigenetic editing into transformative therapies that can expand the promise of genetic medicine and improve the lives of people with serious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amber Salzman
Browse more venture capital transactions:
Prev: 10/19/2026: Vessla venture capital transaction
Next: 10/19/2026: Neonomics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs